Commentary (Fong): Management of Hepatocellular Carcinoma
July 1st 2000Hepatocellular carcinoma (HCC) is the most common solid organ tumor worldwide. In recent decades, diagnosis and treatment of this cancer has evolved significantly. The article by Drs. Nakakura and Choti summarizes many of the advances in this field, delineates the current evidence-based treatment options, and defines promising areas for future study.
NCCN Panel Develops Guidelines for Cancer-Related Fatigue
July 1st 2000FORT LAUDERDALE, Fla-Despite the prevalence of fatigue in cancer patients and survivors, a number of obstacles have stood in the way of its successful treatment, said Barbara F. Piper, DNSc, RN, associate professor, University of Nebraska Medical Center College of Nursing. Patients have been reluctant to bring the symptom to their doctor’s attention out of a concern that they may look like “complainers” or that attending to the symptom will somehow interfere with their cancer treatment.
Magnetic Resonance Imaging of the Abdomen: Applications in the Oncology Patient
June 27th 2000Cross-sectional imaging of the abdomen in oncology patients presents unique challenges and opportunities. A close working relationship between the oncologist and radiologist is essential for the exchange of the clinical and
Genentech Issues Warning on Herceptin
June 2nd 2000SOUTH SAN FRANCISCO-Genentech Inc. has issued a “Dear Doctor” letter to alert physicians to 62 postmarketing reports of serious adverse events related to the use of trastuzumab (Herceptin), the company’s anti-HER-2 monoclonal antibody for use in treating HER-2-positive breast cancer. To date, about 25,000 women have been treated with Herceptin worldwide.
Four From Congress Receive Tsongas Award
June 1st 2000WASHINGTON-Four members of Congress received the Paul E. Tsongas Award from the Lymphoma Research Foundation of America during a Capitol Hill ceremony. The award is presented annually “to recognize outstanding legislative leadership and commitment in support of the health care issues that result in improving the quality of life for all Americans.”
NCI Targets Cancer Disparities With Community-Based Programs
June 1st 2000WASHINGTON-In an effort to better understand and deal with the unequal burden of cancer among various subgroups of US residents, the National Cancer Institute has launched a program to engage members of these minority and underserved populations in community-based cancer control, prevention, research, and training projects.
Promising Results With Targeted Drug Delivery System for Primary Liver Cancer
June 1st 2000FeRx Incorporated, a privately held development stage drug delivery company, recently reported encouraging data from its phase I/II clinical trial of doxorubicin adsorbed to magnetic targeted carriers (MTC-DOX), for the treatment of patients with
SSO President Tells Members: ‘Remember Your Core Values’
June 1st 2000NEW ORLEANS- The “deprofessionalization” of medicine is the greatest challenge faced by physicians today, Glenn D. Steele, Jr., MD, PhD, said in his presidential address at the Society of Surgical Oncology (SSO) Cancer Symposium. He implored his colleagues to get back on the “high road of first principles” in order to tackle the problems generated by managed care and and other aspects of the current health care climate.
Rapid Dose Titration With Controlled-Release Oxycodone
June 1st 2000MIAMI, Florida-Two separate multicenter trials suggest that dose titration in patients with chronic, moderate to severe pain can be achieved as readily with controlled-release (CR) oral oxyco-done (OxyContin) given once every 12 hours as with an oral intermediate-release (IR) formulation given four times a day.
Standard-Dose Chemo May Have Long-Term Cognitive Effects
June 1st 2000NEW YORK-Preliminary findings from a study of long-term cancer survivors suggest a linkage of cognitive deficits to standard-dose chemotherapy, Timothy Ahles, PhD, reported at the Pan American Congress of Psychosocial and Behavioral Oncology.
Breath Test Identifies Patients Who Should Get Lower Chemotherapy Doses
June 1st 2000A relatively simple technique, pioneered by a North Carolina physician, can distinguish between patients who can metabolize docetaxel (Taxotere) normally and those who need to receive lower doses for safety, according to a recent study. Researchers
ADA Inhibitors: Recent Developments and Future Directions in Low-Grade Lymphoma
June 1st 2000Pentostatin (Nipent) is a nucleoside analog that inhibits the activity of the enzyme adenosine deaminase. Inhibition of adenosine deaminase blocks the deamination of adenosine to inosine and deoxyadenosine to deoxyinosine in the purine
Book Prepares Children for BMT Procedures
June 1st 2000A new book, Me and My Marrow: A Kid’s Guide to Bone Marrow Transplants, helps guide children with cancer through the transplant procedure. The book was inspired by 13-year-old Christina Cuzzone, of Northbrook, Illinois, who was diagnosed with leukemia at age 9 and underwent a BMT. After recovering from the transplant, Christina recognized the need for a book to help other children.
Insufficient Evidence for Antioxidants’ Anticancer Effects: IOM
June 1st 2000WASHINGTON-Scientific studies provide insufficient evidence that consuming high doses of antioxidants in the diet and as supplements can prevent chronic diseases, according to a new report by the Institute of Medicine (IOM), a part of the National Academy of Sci-ences. Indeed, megadoses of some antioxidants may lead to ill health rather than benefits, the report warned.
Positive/Negative Purging System Effective in PBSC Grafts for CLL
June 1st 2000NEW ORLEANS-Positive/negative purging of peripheral blood stem cell (PBSC) grafts allows preparation of highly purified CD34+ fractions and up to 6 log of tumor cell depletion in patients with chronic lymphocytic leukemia (CLL), according to a study conducted at the University of Kiel, Germany. Peter Dreger, MD, reported the results at the 41st annual meeting of the American Society of Hematology (ASH).
ASCO Initiates Study of Quality of Cancer Care
June 1st 2000ASCO-The American Society of Clinical Oncology (ASCO) has embarked upon “one of the most important and far reaching initiatives ever undertaken by any medical specialty society-the National Initiative on Cancer Care Quality (NICCQ),” Joseph S. Bailes, MD, outgoing ASCO president, said at the Society’s 36th annual meeting held in New Orleans.
New Process for Depleting B Cells for Transplant in NHL
June 1st 2000NEW ORLEANS-A nonmagnetic method of depleting B cells during purging before autologous peripheral blood stem cell (PBSC) transplantation greatly decreases the nonspecific cell loss that can occur when cells cross a magnet, as in other techniques. The nonmagnetic method is also simple and quick, John Gribben, MD, of Dana-Farber Cancer Institute, said at the 41st annual meeting of the American Society of Hematology.
Magnetic Resonance Imaging for Intra-abdominal Malignancy
June 1st 2000Accurate imaging of the hepatic and extrahepatic abdomen is an important component of the management of many patients with cancer. Historically, clinicians have relied on computed tomography (CT). The use of intravenous (IV) and oral contrast
Palliative Care Is More Than End-Of-Life Care
June 1st 2000FT. LAUDERDALE, Fla-Palliative care, broadly defined, can benefit cancer patients who are newly diagnosed and who are in active treatment, as well as those who are near death. In creating guidelines for palliative care, the National Comprehensive Cancer Network (NCCN) Palliative Care Panel members found agreement on this point.
ASH Moves to Self-Management at New Location
June 1st 2000WASHINGTON-As part of its move to self-management, the American Society of Hematology (ASH) has moved its offices to a new independent location in Washington, DC. Formerly with an association management firm, the ASH executive committee voted in 1999 for the Society to make the move. Martha Liggett, Esq, will continue to serve as executive director.
Older Cancer Patients Benefit From Geriatric Assessment
June 1st 2000FT. LAUDERDALE, Fla-Older cancer patients are at increased risk for complications of chemotherapy, and such risks must be weighed against the potential benefits of treatment. However, chronologic age is an imprecise gauge of physical condition. A geriatric assessment can help the physician determine the best approach to cancer treatment, Lodovico Balducci, MD, said at the fifth annual conference of the National Comprehensive Cancer Network (NCCN).
Proposed Rules Allow New Role for States in Mammography Regulation
June 1st 2000ROCKVILLE, Md-The FDA has proposed rules that would enable it to authorize states to certify, inspect, and enforce quality standards at mammography facilities within their boarders. The rules would implement a provision of the Mammography Quality Standards Act of 1992 (MQSA) and significantly increase the role of the states in the process.
RF Ablation System for Liver Lesions
June 1st 2000SUNNYVALE, California-RadioTherapeutics Corporation has received clearance from the FDA to market its RF System for the ablation of nonresectable liver lesions. The system, consisting of the RF 2000 Radio-frequency Generator and family of LeVeen Needle Electrodes, provides radiofrequency (RF) energy to heat and destroy soft tissue.
Restrictive Patient Privacy Laws Could Thwart Research
June 1st 2000WASHINGTON-When the National Coalition of Cancer Research (NCCR) brought its concerns about the impact of proposed patient privacy regulations on medical research to Capitol Hill, it got strong confirmation about its fears from the founder of the House Cancer Awareness Working Group.
Mammography in a Digital Age: The Experience at Moffitt
June 1st 2000ORLANDO-The technology for mammography to go digital is here, but it may take 5 or 10 years for the transition because of the higher costs that the newer method entails, Maria Kallergi, PhD, said at the Joint Cancer Conference of the Florida Universities.